Arrhythmias & electrophysiology
Coronary venous ethanol infusion for treatment of refractory ventricular arrhythmias
Authors' conclusion
CVEA can be effective for management of complex VAs refractory to standard RFA with an acceptable safety profile.
Study context
- Population
- Patients who underwent coronary venous ethanol ablation (CVEA) for refractory ventricular tachycardia (VT) or premature ventricular contractions (PVCs)
- Participants
- 30 patients32 ablation procedures
- Comparison
- VT ablation cohort vs PVC ablation cohort
- VT ablation cohortn = 20
- PVC ablation cohortn = 12
- Outcome
- Acute suppression of clinical VT after CVEA
- Follow-up
- Acute
Main finding
As reported in the abstract
VT ablation cohort
75%
15 of 20
- Required additional radiofrequency ablation (RFA)
- 1 (5%)
- Non-inducible at baseline
- 1
- Remained inducible for clinical VT
- 3 (15%)
Further findings
- Acute PVC suppression — PVC ablation cohort
- 92%
VT recurrence · follow-up
- Targeted VT recurred
- 3 (15%)
- New VTs occurred
- 7 cases (35%)
PVC burden · follow-up
- PVC suppression sustained in these 11 patients; PVC burden before
- 24.8% ± 13.9%
- PVC burden after
- 2.1% ± 2.1%
Prior treatment
- Had undergone RFA previously
- 28 patients (93%)
- Failed anti-arrhythmic drugs
- 28
Safety
Complications potentially related to CVEA
- Complete heart block
- 2
- Transient left bundle branch block
- 1
- Pericardial effusion
- 1
- Cardiogenic shock
- 2
Original publication
Coronary venous ethanol infusion for treatment of refractory ventricular arrhythmias. Heart Rhythm. Published 27 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →